WO2003026430A1 - Traitement de la rhinite allergique - Google Patents

Traitement de la rhinite allergique Download PDF

Info

Publication number
WO2003026430A1
WO2003026430A1 PCT/US2002/030178 US0230178W WO03026430A1 WO 2003026430 A1 WO2003026430 A1 WO 2003026430A1 US 0230178 W US0230178 W US 0230178W WO 03026430 A1 WO03026430 A1 WO 03026430A1
Authority
WO
WIPO (PCT)
Prior art keywords
herbs
herb
extracts
disorder
allergic rhinitis
Prior art date
Application number
PCT/US2002/030178
Other languages
English (en)
Inventor
Ching-Hsiang Hsu
Original Assignee
Eastwest Pharmaceuticals International Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastwest Pharmaceuticals International Llc filed Critical Eastwest Pharmaceuticals International Llc
Publication of WO2003026430A1 publication Critical patent/WO2003026430A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • One aspect of this invention relates to a nutraceutical composition containing extracts of at least three or four herbs, wherein the first herb, which is optional, is Hedysarum polybotrys Hand. -Mazz. ox Astragalus membranceus Bge. (e.g., its root), the second herb is the root of Atractylodes macrocephala kodiz (e.g., its root), the third herb is Ledebouriella seseloides (hoffm.) Wolff (e.g., its root), and the fourth herb is an anti-allergy herb.
  • An anti-allergy herb is one that, when used alone or in combination with other herbs, can exhibit activity in treating allergy.
  • the weight percentage of the herbal extracts in the nutraceutical composition ranges from 1% to 99%.
  • the fourth herb is Centipeda minimal (L.) A. Br. Et Aschers (e.g., its whole plant, "E-Bu-Shi-Cao" in Chinese). They include those wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5). As indicated by this weight ratio, the first herb may not be included. In other words, the nutraceutical compositions may contain extracts of only three herbs.
  • weight refers to "dry weight,” i.e., the weight measured after the herb have been harvested and dried.
  • drying processes are specified by the regulations in herb-producing countries (e.g., P.R. China). Herbs so-obtained are suitable for transportation and long term storage.
  • the fourth herb is Magnolia lilifora Desr. (e.g., its flower; "Xin-Yi-Hua” in Chinese). They include those wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5- 1.5):(0.5-1.5); and those containing extracts of four herbs.
  • each composition contains extracts of exactly three or four herbs.
  • the weight ratio of the first, second, third, and fourth herbs can be (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
  • Another aspect of this invention relates to a method of treating a disorder related to excessive secretion of histamine or interleukin-4.
  • the method includes administering to a subject in need thereof a nutraceutical composition containing extracts of at least three or four herbs, wherein the first herb, which is optional, is Hedysarum polybotrys Hand.-Mazz. or Astragalus membranceus Bge. (e.g., the root), the second herb is Atractylodes macrocephala kodiz. (e.g., the root), the third herb is Ledebouriella seseloides (hoffm.) Wolff (e.g., the root), and the fourth herb is an anti- allergy herb.
  • the disorder to be treated include, but are not limited to, allergic rhinitis, asthma, and eczyma.
  • compositions used in the method of treating such a disorder include those wherein the fourth herb is Centipeda minimal (L.) A. Br. EtAschers (whole plant) or Magnolia lilifora Desr (flower); those wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5); and those containing extracts of three or four herbs.
  • the improved herbal medicine includes extracts of at least three or four herbs, wherein the first herb, which is optional, is the root of Hedysarum polybotrys Hand.-Mazz. or Astragalus membranceus Bge., the second herb is the root of Atractylodes macrocephala kodiz., the third herb is the root of Ledebouriella seseloides (hoffm.) Wolff, and the fourth herb is an anti-allergy herb.
  • the first herb which is optional, is the root of Hedysarum polybotrys Hand.-Mazz. or Astragalus membranceus Bge.
  • the second herb is the root of Atractylodes macrocephala kodiz.
  • the third herb is the root of Ledebouriella seseloides (hoffm.) Wolff
  • the fourth herb is an anti-allergy herb.
  • a nutraceutical composition of this invention includes extracts of the root of Hedysarum polybotrys Hand.-Mazz. ox Astragalus membranceus Bge., the root of Atractylodes macrocephala kodiz., the root of Ledebouriella seseloides (hoffm.)
  • the weight ratio of the extracts of the first, second, third, and fourth herbs can be in the range of (0-1.5):(0.5-1.5):(0.5- 1.5):(0.5-1.5). Preferred ratios can be determined by efficacy-evaluating methods described below or analogous methods.
  • the nutraceutical composition is unexpectedly effective for the treatment of disorders related to excessive secretion of histamine or interleukin-4, such as allergic rhinitis, asthma, and eczyma.
  • the extracts of the herbs can be obtained by methods well known in the art. For instance, each herb is first soaked in water and then heated (e.g., at 100°C), or first soaked in a mixture of water and an organic solvent (e.g., ethanol) and then heated (e.g., at 55°C) for an extended period of time (e.g., 1-4 hours). The liquid phase, which contains active ingredients from the herbs, is then collected. The solvent (or the solvents) of the solution thus obtained, i.e., water (or a mixture of water and the organic solvent), is then removed under reduced pressure, yielding a residue (i.e., extracts of the herbs). The herbs can be handled together or individually to obtain their extracts.
  • each herb is first soaked in water and then heated (e.g., at 100°C), or first soaked in a mixture of water and an organic solvent (e.g., ethanol) and then heated (e.g., at 55°C) for an extended period of time (e.g.
  • the extracts thus obtained can be used to formulate a nutraceutical composition for treating (including preventing or ameliorating the symptoms of) a disorder related to excessive secretion of histamine or interleukin-4, such as allergic rhinitis, asthma, and eczyma.
  • the nutraceutical composition can be a dietary supplement (e.g., a capsule or tablet, or placed in a mini-bag), a food product (e.g., a soft drink, milk, juice, or confectionary, or placed in a herbal tea-bag), or a botanical drug.
  • the botanical drug can be in a form suitable for oral use, such as a tablet, a hard or soft capsule, an aqueous, or a syrup; or in a form suitable for parenteral use, such as an aqueous propylene glycol solution, or a buffered aqueous solution.
  • the amounts of the active ingredients in the nutraceutical composition depend to a large extent on a subject's specific need. The amount will also vary, as recognized by those skilled in the art, depending on administration route, and possible co-usage of other agents useful for treating the above-mentioned disorders.
  • Herbal extracts thus obtained in an effective amount can also be formulated with a pharmaceutically acceptable carrier into a pharmaceutical composition for treating the above-mentioned disorders.
  • “An effective amount” refers to the amount of the extracts which is required to confer therapeutic effect on the treated subject.
  • Effective doses will vary, as recognized by those skilled in the art, depending on the route of administration, the excipient usage, and the optional co-usage with other therapeutic treatments.
  • pharmaceutically acceptable carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10.
  • the herbal extracts can be formulated into dosage forms for different administration routes utilizing conventional methods. For example, they can be formulated in a capsule, a gel seal, or a tablet for oral administration. Capsules may contain any standard pharmaceutically acceptable materials such as gelatin or cellulose. Tablets may be formulated in accordance with conventional procedures by compressing mixtures of the polysaccharide with a solid carrier and a lubricant. Examples of a suitable solid carrier include starch and sugar bentonite.
  • the herbal extracts can also be administered in the form of a hard shell tablet or a capsule containing a binder, e.g., lactose or mannitol, a conventional filler, and a tableting agent.
  • the pharmaceutical composition may be administered via a parenteral route, e.g., topically, intraperitoneally, and intravenously.
  • parenteral dosage forms include aqueous solutions, isotonic saline or 5% glucose of the active agent, or other well- known pharmaceutically acceptable excipient.
  • Cyclodextrins, or other solubilizing agents well known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compound.
  • nutraceutical or pharmaceutical composition of this invention in inhibiting the secretion of histamine or interleukin-4 can be evaluated by an in vitro assay well known in the art. See, e.g., Cheng et al., M. Taiwan J. Med., 1998, 3:166- 173; and Cheng et al., J. of E.N.T. Medicine, 1998, 33: 431-441.
  • a nutraceutical composition of this invention can be further evaluated by clinical studies.
  • a group of patients suffering from allergic rhinitis (which is related to excessive excretion of histamine or interleukin-4) can be treated with the nutraceutical composition. Before the treatment, they exhibit some symptoms typical of allergic rhinitis including stuffy nose, sneezing, runny nose, itchy nose, itchy eyes, watery eyes, swollen eyes, and sore eyes.
  • the patients are then orally administered with the nutraceutical composition, e.g., by a dose of 800 mg/lOkg/day, for an extended period of time, e.g., 14 days.
  • Relief of the allergy can be observed, as characterized by reduced severity, and sometimes frequency, of the symptoms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition nutraceutique contenant des extraits d'au moins trois ou quatre herbes. La première herbe, facultative, est Hedysarum polybotrys Hand.-Mazz. ou Astragalus membranceus Bge., la deuxième herbe est Atractylodes macrocephala kodiz, la troisième herbe est Ledebouriella seseloides (hoffm.) Wolff, et la quatrième herbe est une herbe anti-allergique. L'invention concerne également un procédé de traitement d'un trouble associé à une secrétion excessive d'histamine ou d'interleukine-4 au moyen des extraits selon l'invention.
PCT/US2002/030178 2001-09-25 2002-09-23 Traitement de la rhinite allergique WO2003026430A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32476101P 2001-09-25 2001-09-25
US60/324,761 2001-09-25
US35000402P 2002-01-17 2002-01-17
US60/350,004 2002-01-17
CA002438055A CA2438055A1 (fr) 2001-09-25 2003-08-22 Traitement de la rhinite allergique

Publications (1)

Publication Number Publication Date
WO2003026430A1 true WO2003026430A1 (fr) 2003-04-03

Family

ID=34426454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/030178 WO2003026430A1 (fr) 2001-09-25 2002-09-23 Traitement de la rhinite allergique

Country Status (2)

Country Link
CA (1) CA2438055A1 (fr)
WO (1) WO2003026430A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102688314A (zh) * 2012-03-27 2012-09-26 荆金锁 一种治疗鼻炎的中药
CN110179908A (zh) * 2019-03-28 2019-08-30 曾子芸 一种鼻窍通香囊及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460578A (en) * 1980-12-11 1984-07-17 Claude Marie Henri Cervelle Pharmaceutical composition for topical use based on a total extract of Hedysarum fructescens willd
US5133964A (en) * 1987-07-01 1992-07-28 Kim Young S Pharmaceutical liquid composition containing bezoar bovis and preparation for its manufacture
US5135010A (en) * 1991-08-09 1992-08-04 Fan Sophie S M Herbal smoking materials
US5942233A (en) * 1996-03-12 1999-08-24 Chang; Teh Shan Herbal composition for stimulating blood circulation
US6280751B1 (en) * 1997-03-10 2001-08-28 Jane Clarissa Fletcher Essential oil composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460578A (en) * 1980-12-11 1984-07-17 Claude Marie Henri Cervelle Pharmaceutical composition for topical use based on a total extract of Hedysarum fructescens willd
US5133964A (en) * 1987-07-01 1992-07-28 Kim Young S Pharmaceutical liquid composition containing bezoar bovis and preparation for its manufacture
US5135010A (en) * 1991-08-09 1992-08-04 Fan Sophie S M Herbal smoking materials
US5942233A (en) * 1996-03-12 1999-08-24 Chang; Teh Shan Herbal composition for stimulating blood circulation
US6280751B1 (en) * 1997-03-10 2001-08-28 Jane Clarissa Fletcher Essential oil composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102688314A (zh) * 2012-03-27 2012-09-26 荆金锁 一种治疗鼻炎的中药
CN110179908A (zh) * 2019-03-28 2019-08-30 曾子芸 一种鼻窍通香囊及其制备方法

Also Published As

Publication number Publication date
CA2438055A1 (fr) 2005-02-22

Similar Documents

Publication Publication Date Title
CN102145061B (zh) 一种治疗过敏性鼻炎的药物及其制备方法
CN101095895A (zh) 用于妇科阴道保洁、保健并治疗妇科阴道疾病的外用药剂及其制法
KR20040030370A (ko) 알레르기성 질환 증상의 개선 기능을 갖는 생약조성물을함유하는 기능성 식품
CN101011562B (zh) 参芪温胆汤新剂型及其生产方法
US20040137084A1 (en) Treatment of allergic rhinitis
CN101172155A (zh) 生脉温胆汤新剂型及其生产方法
RU2442598C1 (ru) Мочегонное средство
US20030059485A1 (en) Treatment of allergic rhinitis
WO2023088488A1 (fr) Composition de médecine chinoise traditionnelle pour la prévention et le traitement de maladies du cerveau, son procédé de préparation et son application
WO2020187017A1 (fr) Composition de médecine chinoise traditionnelle pour relâcher les intestins afin de soulager la constipation, son procédé de préparation et son application
CN107890528B (zh) 一种治疗高尿酸血症的中药组合物及其制备方法
CN109908202A (zh) 一种治疗高尿酸血症的药物组合物及其制备方法
WO2003026430A1 (fr) Traitement de la rhinite allergique
CN101716269A (zh) 一种治疗原发性高血压病的中药组合物
CN103417595B (zh) 一种中药组合物及其制备方法
CN1202852C (zh) 治疗风寒感冒的中药制剂及其制备方法
CN102274428B (zh) 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用
CN105833043A (zh) 一种中药组合物在制备治疗原发性高血压药物中的用途
CN116270910B (zh) 一种清暑补液补电解质抗疲劳组合物及其制备方法
JP2003226650A (ja) 医薬用組成物
CN100450529C (zh) 一种治疗中风后遗症的中药制剂
CN107865953B (zh) 治疗流涎和夜尿增多的中药复方制剂、其制备方法和应用
CN105687499A (zh) 一种含有倍他洛尔的治疗高血压的药物组合物及其制备方法
CN100361673C (zh) 乳增宁及中药组合物在制备治疗黄褐斑病药物中的应用
CN113456739A (zh) 一组针对肝郁气滞甲亢与脱发的中药复合物及其制备方式

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP